Weight Loss & MetabolicStrong Evidence

Orforglipron Peptide Therapy

Benefits, Side Effects, Cost & Protocols

Orforglipron peptide molecular structure diagram from PubChem

Orforglipron is an experimental oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable semaglutide and tirzepatide, it is a small molecule taken daily by mouth, potentially offering a more convenient weight loss and diabetes treatment option.

ByChris Riley(CFA)&Alex Evans, PharmD, MBA(PharmD, MBA)|Updated May 19, 2026

Clinically Reviewed

Reviewed by Alex Evans, PharmD, MBA · Updated May 2026

Evidence-Based

Sourced from FDA, PubMed & ClinicalTrials.gov · View sources

FDA Status

FDA-approved drug

Evidence

Strong Evidence

Who Is Orforglipron Best For?

Oral administration (no injection)Weight loss potentialBlood sugar regulationConvenient daily pill

How Orforglipron Works

Small-molecule oral GLP-1 receptor agonist that activates the same pathways as injectable GLP-1 drugs without requiring injection.

Orforglipron FAQ

What is ORFORGLIPRON?

Orforglipron is an investigational oral non-peptide GLP-1 receptor agonist being developed by Eli Lilly. Currently in Phase 3 clinical trials, it could become the first oral non-peptide GLP-1 agonist if approved.

How does ORFORGLIPRON work?

Small-molecule oral GLP-1 receptor agonist that activates the same pathways as injectable GLP-1 drugs without requiring injection.

Is ORFORGLIPRON legal to buy?

ORFORGLIPRON is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy ORFORGLIPRON?

ORFORGLIPRON is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does ORFORGLIPRON belong to?

ORFORGLIPRON is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of ORFORGLIPRON?

ORFORGLIPRON has been studied for: Oral administration (no injection), Weight loss potential, Blood sugar regulation, Convenient daily pill. Phase 3 trials by Eli Lilly. First oral non-peptide GLP-1 agonist if approved.

Key Studies

85 total on PubMed0

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Wharton S, Aronne LJ, Stefanski A et al

N Engl J MedPhase 3

Orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks.

Orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Horn DB, Ryan DH, Kis SG et al

LancetPhase 3

Orforglipron 36 mg reduced body weight by 9.6% vs 2.5% placebo in adults with obesity and type 2 diabetes.

Orforglipron 36 mg reduced body weight by 9.6% vs 2.5% placebo in adults with obesity and type 2 diabetes

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Rosenstock J, Hsia S, Nevarez Ruiz L et al

N Engl J MedPhase 3

Orforglipron reduced HbA1c by 1.24-1.48 percentage points and body weight by 4.5-7.6% versus placebo.

Orforglipron reduced HbA1c by 1.24-1.48 percentage points and body weight by 4.5-7.6% versus placebo

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

Orforglipron Compound Data

Molecular Formula

C48H48F2N10O5

Molecular Weight

883.0 g/mol

IUPAC Name

3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one

View full compound on PubChem

Orforglipron News

What Is Orforglipron? Inside a CU Anschutz Clinical Trial for a New Oral GLP-1 Weight Loss Drug - CU Anschutz newsroom

CU Anschutz newsroom · today

Orforglipron News: Foundayo FDA Approved for Weight loss - GoodRx

GoodRx · 2 days ago

Orforglipron (Foundayo) expands oral treatment options for weight management - 2 Minute Medicine

2 Minute Medicine · 10 days ago

Lilly’s weight-loss pill wins FDA approval - ACS Publications

ACS Publications · 28 days ago

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial - PR Newswire

PR Newswire · 8 months ago

News aggregated via Google News. Inclusion does not imply endorsement.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptide therapies have not been evaluated by the FDA for most listed indications.All prices shown are estimates based on publicly available data and may not reflect current pricing — providers and brands set their own prices and can change them at any time. Always verify pricing directly with the provider before purchasing. Consult a licensed healthcare provider before starting any peptide protocol.

Ready to explore Orforglipron with a provider?

Take our 2-minute quiz to get matched with a board-certified provider specializing in Orforglipron.

Take the Quiz →